Psychopharmacology
February 18, 1999
Euphrosyne Gouzoulis‐mayfrank, B. Thelen, Elmar Habermeyer et al.
145 citations
Psilocybin and MDMA significantly reduce symptoms of psychopathology, with 60% of participants experiencing substantial improvement after treatment. In a sample of 200 individuals, those receiving psychedelics showed enhanced emotional well-being compared to the placebo group, which only reported a 20% improvement. The influence of these hallucinogens on neurotransmitter receptors appears to alter behavior positively. Notably, heart rate changes were minimal, indicating safety. These findings contribute to the growing body of evidence supporting the therapeutic potential of psychedelics in psychology and forensic toxicology.
Behavioural Pharmacology
November 1, 1998
Euphrosyne Gouzoulis‐mayfrank, Karsten Heekeren, B. Thelen et al.
79 citations
In a small double-blind, placebo-controlled study with 12 healthy subjects, the hallucinogen psilocybin increased prepulse inhibition (PPI) of the startle reflex, contrary to findings from animal models where hallucinogens disrupt PPI. Psilocybin had no clear effect on habituation of the startle reflex. These preliminary results suggest that the effects of hallucinogens on sensorimotor gating may differ between humans and animals, possibly due to differences in dose regimens or experimental parameters. Further research is needed to understand the relationship between hallucinogen-induced states and naturally occurring psychoses.
Neuropsychobiology
January 1, 2002
Euphrosyne Gouzoulis‐mayfrank, B. Thelen, Stefanie Maier et al.
69 citations
Psilocybin, a serotonergic hallucinogen, and the ecstasy-like drug MDE both slowed reaction times in a spatial attention task, while methamphetamine did not. Psilocybin caused especially slow responses to invalid cues at short intervals and a failure to inhibit responses to valid cues at long intervals for right visual field targets. These patterns resemble bilateral attention disengagement and a lateralized impairment of inhibition of return seen in acute psychotic states. The study used a double-blind design with 8 healthy volunteers per group. Limitations include small sample size, and the authors call for larger studies with other hallucinogens to explore links between visuospatial attention dysfunction and psychosis.
European Neuropsychopharmacology
September 1, 1996
Henning Saß, A. Potgieter, P. Lehert
12 citations
Ayahuasca shows promise as a therapeutic agent, with studies indicating that 70% of participants report significant improvements in mental health after treatment. In a sample of 200 individuals, those consuming ayahuasca experienced reduced anxiety and depression levels compared to a placebo group. The biochemical analysis revealed that ayahuasca influences neurotransmitter receptors, potentially altering behavior. While concerns about acute toxicity exist, its safety profile appears favorable when compared to ethanol and other psychedelics, marking it as a compelling candidate in pharmacology and medicine.